Haleon Raises $2 Billion in Three-Tranche Bond Offering to Refinance 2027 Notes
The U.K. consumer health giant priced fixed-rate USD bonds across 2029, 2031, and 2036 maturities, with proceeds earmarked for a concurrent tender offer.
Bond Offering Details
Haleon plc disclosed that its wholly-owned subsidiary, Haleon US Capital LLC, launched and priced a $2 billion SEC-registered bond offering on August 12, 2026, with settlement scheduled for August 21 (6-K filing, 2026-08-13). The consumer health company, which houses brands including Sensodyne, Advil, and Centrum, structured the offering across three tranches of senior fixed-rate notes.
The issuance comprises $600 million of 4.625% notes maturing in 2029, $600 million of 4.875% notes maturing in 2031, and $800 million of 5.375% notes maturing in 2036 (6-K filing, 2026-08-13). Payment of principal and interest is fully and unconditionally guaranteed by Haleon plc, the London-listed parent company with a market capitalization of approximately $42 billion.
Refinancing Strategy
The company stated it "expects to use the net proceeds of the Offering together with cash on hand, if necessary, to repurchase in whole or in part the Issuer's outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027 in the concurrent tender offer announced on 11 August 2026, and for general purposes of the Company and its subsidiaries" (6-K filing, 2026-08-13).
The refinancing effectively extends Haleon's debt maturity profile while adjusting its cost of capital. The 2027 notes carry a 3.375% coupon, notably lower than the new issuance rates, reflecting the changed interest rate environment since those securities were originally issued.
Market Context
Barclays Capital Inc., BofA Securities, Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, and Mizuho Securities USA LLC served as joint book-running managers on the offering (6-K filing, 2026-08-13). The syndicate of five major investment banks suggests robust institutional demand for the consumer health company's paper.
According to MarginX data, Haleon has been active in share repurchases recently, with buybacks totaling over 18.7 million shares across three disclosed transactions. The company is scheduled to report third-quarter 2026 results on October 30, 2026, MarginX data shows.
Company Profile
Haleon describes itself as "a consumer company that is solely focused on better everyday health" with a portfolio spanning six major categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health (6-K filing, 2026-08-13). The filing notes that Haleon's brands "are trusted by more than one billion consumers and are recommended by health professionals around the world."
The company trades on both the London Stock Exchange and New York Stock Exchange under the ticker HLN, closing at $3.577 on August 12, 2026.
The offering was made through a registration statement (File Nos. 333-297789 and 333-297789-02) filed with the SEC, with detailed documentation available through the commission's EDGAR system (6-K filing, 2026-08-13).
This article was generated by MarginX from the 6-K filing on 2026-08-13. It is not investment advice.